NO20032542D0 - Attenuated anti-CD28 antibodies and their use - Google Patents

Attenuated anti-CD28 antibodies and their use

Info

Publication number: NO20032542D0
Authority: NO; Norway
Prior art keywords: antibodies; attenuated anti; attenuated
Prior art date: 2000-12-14

Application number

NO20032542A

Other languages

Norwegian (no)

Other versions

NO20032542L (en

Inventor

J Yun Tso

Paul Hinton

Maximiliano Vasquez

Kouichi Tamura

Yasuyuki Higashi

Nobuo Seki

Hirotsugu Ueda

Original Assignee

Fujisawa Pharmaceutical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-14

Filing date

2003-06-05

Publication date

2003-06-05

2003-06-05 Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co

2003-06-05 Publication of NO20032542D0 publication Critical patent/NO20032542D0/en

2003-08-07 Publication of NO20032542L publication Critical patent/NO20032542L/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Surgery (AREA)
Transplantation (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20032542A 2000-12-14 2003-06-05 Attenuated anti-CD28 antibodies and their use NO20032542L (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25515500P	2000-12-14	2000-12-14
PCT/US2001/047955 WO2002047721A1 (en)	2000-12-14	2001-12-14	Silensed anti-cd28 antibodies and use thereof

Publications (2)

Publication Number	Publication Date
NO20032542D0 true NO20032542D0 (en)	2003-06-05
NO20032542L NO20032542L (en)	2003-08-07

Family

ID=22967074

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20032542A NO20032542L (en)	2000-12-14	2003-06-05	Attenuated anti-CD28 antibodies and their use

Country Status (18)

Country	Link
EP (1)	EP1341553A4 (en)
JP (1)	JP2004515243A (en)
KR (1)	KR20040020866A (en)
CN (1)	CN1272345C (en)
AR (1)	AR031924A1 (en)
AU (2)	AU2002226086C1 (en)
BR (1)	BR0116686A (en)
CA (1)	CA2432736A1 (en)
CZ (1)	CZ20031909A3 (en)
HU (1)	HUP0400697A3 (en)
IL (1)	IL156262A0 (en)
MX (1)	MXPA03005327A (en)
NO (1)	NO20032542L (en)
NZ (1)	NZ526569A (en)
PL (1)	PL363239A1 (en)
RU (1)	RU2261723C2 (en)
WO (1)	WO2002047721A1 (en)
ZA (1)	ZA200305384B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080095774A1 (en) *	2001-02-16	2008-04-24	Wyeth	Agents and Methods for Specifically Blocking CD28-Mediated Signaling
WO2002066059A2 (en)	2001-02-16	2002-08-29	Genetics Institute, Llc	Agents that specifically block cd28-mediated signaling and uses therefor
BRPI0611901A2 (en)	2005-06-14	2012-08-28	Amgen, Inc	composition, lyophilized kit and process for preparing a composition
FR2951176A1 (en)	2009-10-09	2011-04-15	Tcl Pharma	MONOVALENT LIGANDS OF THE HUMAN CD28 RECEPTOR
LT2536764T (en) *	2010-02-18	2018-10-25	Ose Immunotherapeutics	Anti-cd28 humanized antibodies
PT3528787T (en)	2016-10-21	2026-03-11	Amgen Inc	Pharmaceutical formulations and methods for producing them.
KR20210035805A (en)	2018-06-15	2021-04-01	플래그쉽 파이어니어링 이노베이션스 브이, 인크.	Increased immune activity through regulation of postcellular signaling factors
CA3130348A1 (en) *	2019-03-14	2020-09-17	Motti HAKIM	A method for immunosuppression
WO2020227159A2 (en)	2019-05-03	2020-11-12	Flagship Pioneering Innovations V, Inc.	Methods of modulating immune activity
JP2023509803A (en)	2019-12-02	2023-03-09	ビオンドバイオロジクスリミテッド	Use of MMP Suppression
US20230114107A1 (en)	2019-12-17	2023-04-13	Flagship Pioneering Innovations V, Inc.	Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
US20230355804A1 (en)	2020-06-29	2023-11-09	Flagship Pioneering Innovations V, Inc.	Viruses engineered to promote thanotransmission and their use in treating cancer
CA3192204A1 (en)	2020-08-19	2022-02-24	Xencor, Inc.	Anti-cd28 and/or anti-b7h3 compositions
EP4313109A1 (en)	2021-03-31	2024-02-07	Flagship Pioneering Innovations V, Inc.	Thanotransmission polypeptides and their use in treating cancer
AU2022303363A1 (en)	2021-06-29	2024-01-18	Flagship Pioneering Innovations V, Inc.	Immune cells engineered to promote thanotransmission and uses thereof
US12365743B2 (en)	2022-02-23	2025-07-22	Xencor, Inc.	Anti-CD28 x anti-PSMA antibodies
WO2024040194A1 (en)	2022-08-17	2024-02-22	Capstan Therapeutics, Inc.	Conditioning for in vivo immune cell engineering
US20240174732A1 (en)	2022-10-05	2024-05-30	Flagship Pioneering Innovations V, Inc.	Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024148336A1 (en) *	2023-01-06	2024-07-11	Igm Biosciences, Inc.	T cell costimulatory multimeric binding molecules and uses thereof
WO2024151687A1 (en)	2023-01-09	2024-07-18	Flagship Pioneering Innovations V, Inc.	Genetic switches and their use in treating cancer
AU2024279278A1 (en)	2023-05-31	2025-12-18	Capstan Therapeutics, Inc.	Lipid nanoparticle formulations and compositions
US20250127728A1 (en)	2023-10-05	2025-04-24	Capstan Therapeutics, Inc.	Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en)	2023-10-05	2025-04-10	Capstan Therapeutics, Inc.	Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en)	2024-02-22	2025-10-02	Capstan Therapeutics, Inc.	Immune engineering amplification
WO2025217452A1 (en)	2024-04-11	2025-10-16	Capstan Therapeutics, Inc.	Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en)	2024-04-11	2025-10-16	Capstan Therapeutics, Inc.	Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6641809B1 (en) *	1990-03-26	2003-11-04	Bristol-Myers Squibb Company	Method of regulating cellular processes mediated by B7 and CD28

2001
- 2001-12-14 KR KR10-2003-7007798A patent/KR20040020866A/en not_active Ceased
- 2001-12-14 AR ARP010105828A patent/AR031924A1/en unknown
- 2001-12-14 EP EP01995504A patent/EP1341553A4/en not_active Withdrawn
- 2001-12-14 NZ NZ526569A patent/NZ526569A/en unknown
- 2001-12-14 RU RU2003121231/15A patent/RU2261723C2/en not_active IP Right Cessation
- 2001-12-14 CZ CZ20031909A patent/CZ20031909A3/en unknown
- 2001-12-14 AU AU2002226086A patent/AU2002226086C1/en not_active Ceased
- 2001-12-14 HU HU0400697A patent/HUP0400697A3/en unknown
- 2001-12-14 MX MXPA03005327A patent/MXPA03005327A/en unknown
- 2001-12-14 AU AU2608602A patent/AU2608602A/en active Pending
- 2001-12-14 PL PL01363239A patent/PL363239A1/en not_active Application Discontinuation
- 2001-12-14 WO PCT/US2001/047955 patent/WO2002047721A1/en not_active Ceased
- 2001-12-14 IL IL15626201A patent/IL156262A0/en unknown
- 2001-12-14 CN CNB018226361A patent/CN1272345C/en not_active Expired - Fee Related
- 2001-12-14 CA CA002432736A patent/CA2432736A1/en not_active Abandoned
- 2001-12-14 JP JP2002549291A patent/JP2004515243A/en not_active Withdrawn
- 2001-12-14 BR BR0116686-7A patent/BR0116686A/en not_active IP Right Cessation
2003
- 2003-06-05 NO NO20032542A patent/NO20032542L/en not_active Application Discontinuation
- 2003-07-11 ZA ZA200305384A patent/ZA200305384B/en unknown

Also Published As

Publication number	Publication date
CA2432736A1 (en)	2002-06-20
ZA200305384B (en)	2004-10-11
EP1341553A1 (en)	2003-09-10
HUP0400697A2 (en)	2004-06-28
AR031924A1 (en)	2003-10-08
CN1272345C (en)	2006-08-30
WO2002047721A1 (en)	2002-06-20
RU2003121231A (en)	2005-02-10
AU2002226086C1 (en)	2006-03-09
CN1489473A (en)	2004-04-14
EP1341553A4 (en)	2004-07-28
RU2261723C2 (en)	2005-10-10
CZ20031909A3 (en)	2003-11-12
AU2002226086B2 (en)	2005-08-25
NO20032542L (en)	2003-08-07
PL363239A1 (en)	2004-11-15
NZ526569A (en)	2005-07-29
AU2608602A (en)	2002-06-24
IL156262A0 (en)	2004-01-04
KR20040020866A (en)	2004-03-09
HUP0400697A3 (en)	2007-05-02
JP2004515243A (en)	2004-05-27
MXPA03005327A (en)	2004-12-03
BR0116686A (en)	2003-12-30

Legal Events

Date	Code	Title	Description
2006-02-06	CREP	Change of representative	Representative=s name: PLOUGMANN 6 VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0
2007-08-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20032542L (en)	2003-08-07	Attenuated anti-CD28 antibodies and their use
CY2019029I2 (en)	2020-05-29	ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES
DK1390389T3 (en)	2009-04-20	Crypto-blocking antibodies and uses thereof
NO20034405L (en)	2003-12-05	Anti-cheese pontine antibody and its use
IS6779A (en)	2003-04-11	Human antibody against LT-beta-R
DK1691837T3 (en)	2012-10-01	IP-10 antibodies and their use
DK1417175T3 (en)	2013-10-28	SUBSTITUTED DIHYDRO-3-HALO-1H-PYRAZOL-5-CARBOXYLATES AND PREPARATION AND USE THEREOF
DK1122244T3 (en)	2004-10-25	Uracil compounds and their use
NO20033418L (en)	2003-09-30	Immune regulatory antibodies and their use
NO20030614L (en)	2003-04-02	Anti-IL-12 Antibodies, Compositions, Methods and Uses
IS7040A (en)	2003-11-17	5-HT receptors and their use
NO20021449D0 (en)	2002-03-22	Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use
TWI316088B (en)	2009-10-21	Anti-tnf alpha antibodies and their uses
DK1711207T3 (en)	2013-03-11	Interferon-alpha antibodies and their use
IS6411A (en)	2002-06-06	Kaspasa inhibits and their use
FI20002210L (en)	2002-04-07	Wrist device
NO20033456L (en)	2003-10-06	Modified and stabilized GDF propeptides and their use
NO20033387L (en)	2003-09-25	Modified antibodies and methods of use
DK1278763T3 (en)	2007-06-11	3-Nitrogen-6,7-dioxygen steroids and related applications
FI20002209L (en)	2002-04-07	Wrist device
DK1339292T3 (en)	2010-04-12	Composition and method
DK1322597T3 (en)	2012-07-02	Process and intermediate
DK1317478T3 (en)	2007-05-07	The distinction between GnRH-I and GnRH-II
NO20032821D0 (en)	2003-06-19	Sea-trosy and related practices
IS6570A (en)	2002-09-27	Pressure-reducing agents and use